Pan Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pan Liu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Chaodan Yang
Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Dept Pathol, Hangzhou 310022, Zhejiang, Peoples R China
1 shared publication - Chen Xu
Chinese Acad Sci, Zhejiang Canc Inst, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Hangzhou 310022, Zhejiang, Peoples R China
1 shared publication - Chenyang Xu
Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
1 shared publication - Conghui Wu
Chinese Acad Sci, Zhejiang Canc Inst, Zhejiang Canc Hosp, Hangzhou Inst Med HIM, Hangzhou 310022, Zhejiang, Peoples R China
1 shared publication - Dan Su
Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, China
1 shared publication - Hui Guo
MiRXES Hangzhou Biotechnol Co LTD, Hangzhou, Peoples R China
1 shared publication
Latest Publications
- Open Access
- 16 February 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
FCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy
Immunotherapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tum
- 16 February 2026
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 24 (1)
Open AccessFCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy
Immunotherapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tum
- 29 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 195, 107902
A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel
- 29 July 2024
- Published by Elsevier in Lung Cancer
- Vol. 195, 107902
A predictive model for prognostic risk stratification of early-stage NSCLC based on clinicopathological and miRNA panel